
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical is poised to continue its strong growth in the biopharmaceutical industry due to its diversified product portfolio for the treatment of ADHD and moderate to severe pain. The company's recent guidance, increase in its Jornay PM sales estimates, and expansion of its sales force and digital efforts all point to strong potential for revenue growth in 2026 and beyond. Additionally, with a strong operating cash flow margin and the recently-enhanced balance sheet, the company is well-positioned for potential business development opportunities and creating shareholder value. Despite potential pressure from generic competition in the Nucynta franchise, we maintain our Buy rating and raise our price target to $60 from $46.
Bears say
Collegium Pharmaceutical is facing potential challenges with generic erosion on its pain portfolio, which could impact future revenues and overall profitability. Despite efforts to pursue potential acquisitions through a newly obtained credit facility, the company's heavy reliance on third-party suppliers for its DETERx technology raises concerns about potential disruptions in the commercialization of its products. Furthermore, the company's current financials show increasing costs of goods sold, which could further impact its profitability in the long run.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares